Latest Period
Q2 2026
Security Snapshot
Ascendis Pharma A/S - Common Stock (ASND) Institutional Ownership
CUSIP: 04351P101
13F Institutional Holders and Ownership History from Q1 2015 to Q2 2026
Institutions Reporting
11
Shares (Excl. Options)
1,055,356
Price
$266.72
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ASND on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 1,055,356
- Total 13F value
- $281,484,219
- Portfolio coverage rank
- 0%
- Share change
- -53,348,944
- Value change
- -$12,164,842,841
- Number of holders
- 11
- Shares outstanding
- 62,915,156
- SEC-reported price per share
- $266.72
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ASND - Ascendis Pharma A/S - Common Stock is tracked under CUSIP 04351P101.
- 11 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 266 to 11 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $12,504,610,400 to $281,484,219.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 11 institutions filings for Q2 2026.
Security key
04351P101
Latest holder period
Q2 2026
13F holders
11
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
ASND full holder history
Ascendis Pharma A/S SEC filings
Ascendis Pharma A/S company facts
Ascendis Pharma A/S insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 04351P101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
ASND
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10% | +114% | $1,617,120,732 | +$954,097,949 | 6,506,219 | +144% | T. Rowe Price Investment Management, Inc. | 30 Apr 2026 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 8.5% | -7.8% | $1,115,183,925 | -$73,663,872 | 5,185,696 | -6.2% | Westfield Capital Management Company, L.P. | 31 Dec 2025 |
| FMR LLC | 6.6% | -18% | $957,439,699 | -$197,557,979 | 3,852,101 | -17% | FMR LLC | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 6% | -22% | $924,469,795 | -$150,026,520 | 3,719,452 | -14% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| Artisan Partners Limited Partnership | 5.2% | $687,887,717 | 3,225,885 | Artisan Partners Asset Management Inc. | 31 Dec 2025 | |||
| Capital International Investors | 3.2% | -40% | $492,207,917 | -$267,935,411 | 2,013,285 | -35% | Capital International Investors | 31 Mar 2026 |
As of 30 Jun 2026, 11 institutional investors reported holding 1,055,356 shares of Ascendis Pharma A/S - Common Stock (ASND). This represents 1.7% of the company’s total 62,915,156 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
46
Latest
Q2 2026
Rows shown
1-25 of 46
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 1,055,356 | $281,484,219 | -$12,164,842,841 | $266.72 | 11 |
| 2026 Q1 | 54,718,678 | $12,504,610,400 | -$2,135,196,263 | $228.73 | 266 |
| 2025 Q4 | 64,677,198 | $13,781,007,160 | +$36,599,194 | $213.24 | 304 |
| 2025 Q3 | 63,798,487 | $12,683,838,954 | +$232,138,786 | $198.81 | 279 |
| 2025 Q2 | 62,895,390 | $10,855,906,781 | -$373,773,069 | $172.60 | 245 |
| 2025 Q1 | 65,180,066 | $10,147,446,038 | +$223,136,493 | $155.86 | 241 |
| 2024 Q4 | 63,751,521 | $8,776,308,689 | +$115,863,512 | $137.67 | 212 |
| 2024 Q3 | 62,595,716 | $9,312,956,409 | +$237,478,312 | $149.31 | 218 |
| 2024 Q2 | 60,687,245 | $8,276,478,215 | -$25,623,552 | $136.38 | 202 |
| 2024 Q1 | 60,791,422 | $9,189,438,728 | +$198,420,492 | $151.17 | 188 |
| 2023 Q4 | 60,262,338 | $7,590,188,894 | -$95,295,592 | $125.95 | 183 |
| 2023 Q3 | 60,279,508 | $5,644,577,484 | -$61,738,785 | $93.64 | 157 |
| 2023 Q2 | 61,039,136 | $5,447,708,812 | -$42,606,636 | $89.25 | 156 |
| 2023 Q1 | 60,982,797 | $6,535,152,679 | -$603,913,240 | $107.22 | 160 |
| 2022 Q4 | 65,956,055 | $8,054,269,679 | -$66,421,048 | $122.13 | 183 |
| 2022 Q3 | 66,716,414 | $6,891,080,476 | +$149,538,106 | $103.26 | 177 |
| 2022 Q2 | 63,211,628 | $5,875,622,934 | +$99,259,708 | $92.96 | 162 |
| 2022 Q1 | 61,928,932 | $7,267,064,424 | +$416,027,513 | $117.36 | 169 |
| 2021 Q4 | 58,376,386 | $7,851,336,290 | -$60,447,865 | $134.53 | 168 |
| 2021 Q3 | 58,008,737 | $9,244,880,979 | +$506,030,857 | $159.39 | 162 |
| 2021 Q2 | 55,049,436 | $7,239,726,130 | +$277,622,452 | $131.55 | 167 |
| 2021 Q1 | 52,687,197 | $6,790,538,552 | -$259,999,867 | $128.88 | 172 |
| 2020 Q4 | 54,357,110 | $9,065,494,890 | +$123,538,090 | $166.78 | 173 |
| 2020 Q3 | 53,548,292 | $8,263,618,101 | +$776,855,285 | $154.32 | 150 |
| 2020 Q2 | 48,248,343 | $7,132,005,530 | +$39,025,561 | $147.90 | 149 |